Prediction of metabolic clearance using fresh human hepatocytes: Comparison with cryopreserved hepatocytes and hepatic microsomes for five benzodiazepines

Xenobiotica

Volumn 38, Issue 4, 2008, Pages 353-367

  Hallifax, D ^a   Galetin, A ^a   Houston, J B ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Benzodiazepines; Clearance prediction; Human hepatocytes

Indexed keywords

ALPRAZOLAM; DIAZEPAM; FLUNITRAZEPAM; MIDAZOLAM; TESTOSTERONE; TRIAZOLAM;

ARTICLE; CELL ACTIVATION; CELL VIABILITY; CRYOPRESERVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; KINETICS; LIVER CELL; LIVER MICROSOME; METABOLIC CLEARANCE RATE;

ALPRAZOLAM; BENZODIAZEPINES; CELL SURVIVAL; CELLS, CULTURED; CRYOPRESERVATION; CYTOCHROME P-450 CYP3A; DIAZEPAM; FLUNITRAZEPAM; HEPATOCYTES; HUMANS; METABOLIC CLEARANCE RATE; MICROSOMES, LIVER; MIDAZOLAM; SUBSTRATE SPECIFICITY; TRIAZOLAM;

EID: 40749102194     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250701834665     Document Type: Article

References (39)

1. Berry MN, Edwards AM, Barritt GJ. 1991. Isolated hepatocytes: preparation, properties and applications. In: Burden RH, Knippenberg PH, editors. Laboratory techniques in biochemistry and molecular biology. New York, NY: Elsevier. p 46.
2. Binda D, Lasserre-Bigot D, Bonet A, Thomassin M, Come MP, Guinchard C, Bars R, Jacqueson A, Richert L. 2003. Time course of cytochromes P450 decline during rat hepatocyte isolation and culture: Effect of L-NAME. Toxicology in Vitro 17:59-67.
3. Brown HS, Griffin M, Houston JB. 2007. Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metabolism and Disposition 35:293-301.
4. Busby WF, Ackermann JR, Crespi CL. 1999. Effect of methanol, ethanol, dimethyl sulfoxide and acetonitrile on in vitro activities of CDNA-expressed human cytochromes P-450 Drug Metabolism. Disposition 27:246-249.
5. Chen Q, Tan E, Strauss JR, Zhang Z, Fenyk-Melody JE, Booth-Genthe C, Rushmore TH, Stearns RA, Evans DC, Baillie TA, et al. 2004. Effect of quinidine on the 10-hydroxylation of R-warfarin: species differences and clearance projection. Journal of Pharmacology and Experimental Therapeutics 311:307-314.
6. Egnell AC, Houston JB, Boyer S. 2003. In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine Journal of Pharmacology and Experimental Therapeutics 305:1251-1262.
7. Fisher RL, Gandolfi AJ, Brendel K. 2001. Human liver quality is a dominant factor in the outcome of in vitro studies. Cell Biology and Toxicology 17:179-189.
8. Griffin JE, Ojeda SR. 2000. Textbook of endocrine physiology. 4th ed. New York, NY: Oxford University Press. p 257.
9. Griffin SJ, Houston JB. 2004. Comparison of fresh and cryopreserved rat hepatocyte suspensions for the prediction of in vitro intrinsic clearance. Drug Metabolism and Disposition 32:552-558.
10. Grime K, Riley RJ. 2006. The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions. Current Drug Metabolism 7:251-264.
11. Hallifax D, Rawden HC, Hazook N, Houston JB. 2005. Prediction of metabolic clearance using cryopreserved human hepatocytes: Kinetic characteristics for five benzodiazepines. Drug Metabolism and Disposition 33:1852-1858.
12. Hewitt NJ, Gomez Lechon MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, et al. 2007. Primary hepatocytes: Current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metabolism Reviews 39:159-234.
13. Hickman D, Wang J-P, Wang Y, Unadkat JD. 1998. Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activity. Drug Metabolism and Disposition 26:207-215.
14. Houston JB. 1994. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochemical Pharmacology 47:1469-1479.
15. Houston JB, Carlile DJ. 1997. Prediction of hepatic clearance from microsomes, hepatocytes and liver slices. Drug Metabolism Reviews 29:891-922.
16. Houston JB, Galetin A. 2005. Modelling atypical CYP3A4 kinetics: Principles and pragmatism. Archives of Biochemistry and Biophysics 433:351-360.
17. Houston JB, Kenworthy KE. 1999. In vitro-in vivo scaling of cytochrome P450 kinetic data not consistent with the classical Michaelis-Menten model. Drug Metabolism and Disposition 28:246-254.
18. Ito K, Houston JB. 2004. Comparison of the use of liver models for prediction of drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharmaceutical Research 21:785-792.
19. Ito K, Houston JB. 2005. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharmaceutical Research 22:103-112.
20. Kenworthy KE, Clarke SE, Andrews J, Houston JB. 2001. Multisite kinetic models for CYP3A4: Simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metabolism and Disposition 29:1644-1651.
21. Lau YY, Sapidou E, Cui X, White RE, Cheng K-C. 2002. Development of a novel in vitro model to predict hepatic clearance using fresh, cryopreserved and sandwich-cultured hepatocytes. Drug Metabolism and Disposition 30:1446-1454.
22. Maenpaa J, Hall SD, Ring BJ, Strom SC. 1998. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: The effect of assay conditions and regioselective stimulation by α-naphthoflavone, terfenadine and testosterone. Pharmacogenetics 8:137-155.
23. McGinnity DF, Soars MG, Urbanowicz RA, Riley RJ. 2004. Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metabolism and Disposition 32:1247-1253.
24. Nakamura H, Nakasa H, Ishii I, Ariyoshi N, Igarashi T, Ohmori S, Kitada M. 2002. Effects of endogenous steroids on CYP3A4-mediated drug metabolism by human liver microsomes. Drug Metabolism and Disposition 30:534-540.
25. Naritomi Y, Terashita S, Kagayama A, Sugiyama Y. 2003. Utility of hepatocytes in predicting drug metabolism: Comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metabolism and Disposition 31:580-588.
26. Ngui JS, Chen Q, Shou M, Wang RW, Stearns RA, Baillie T, Tang W. 2001. In vitro stimulation of warfarin metabolism by quinidine: increases in the formation of 4′-hydroxylation and 10-hydroxywarfarin. Drug Metabolism and Disposition 29:877-886.
27. Ngui JS, Tang W, Stearns RW, Shou M, Miller RR, Zhang Y, Lin JH, Baillie T. 2000. Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. Drug Metabolism and Disposition 28:1043-1050.
28. Patki KC, Von Moltke LL, Greenblatt DJ. 2003. In vitro metabolism of midazolam, triazolam, nifedipine and testosterone by human liver microsomes and recombinant cytochromes P450: role of CYP3A4 and CYP3A5. Drug Metabolism and Disposition 31:938-944.
29. Rawden HC, Carlile DJ, Tindall A, Hallifax D, Galetin A, Ito K, Houston JB. 2005. Microsomal prediction of in vivo clearance and associated inter-individual variability of six benzodiazepines in humans. Xenobiotica 35:603-625.
30. Rawden HC, Tindall A, Hallifax D, Houston JB. 2001. Heteroactivation of CYP3A4 substrates: Impact on intrinsic clearance and inter-individual variability. Drug Metabolism Reviews 33:211.
31. Riley RJ, McGinnity DF, Austin RP. 2005. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metabolism and Disposition 33:1304-1311.
32. Schrag ML, Weinkers LC. 2001. Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site. Drug Metabolism and Disposition 29:70-75.
33. Shibata Y, Takahashi H, Chiba M, Ishii Y. 2002. Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: An application of the serum incubation method. Drug Metabolism and Disposition 30:892-896.
34. Soars MG, Burchell B, Riley RJ. 2002. In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. Journal of Pharmacology and Experimental Therapeutics 301:382-390.
35. Soars MG, McGinnity DF, Grime K, Riley RJ. 2007. The pivotal role of hepatocytes in drug discovery. Drug Metabolism and Disposition 35:859-865.
36. Suzuki S, Sato T, Yoshino H, Kobayashi E. 2004. Impact of warm ischemia time on microsomal P450 isoforms in a porcine model of therapeutic liver resection. Life Science 76:39-46.
37. Tang W, Stearns RA, Kwei GY, Iliff SA, Miller RR, Egan MA, Yu NX, Dean DC, Kumar S, Shou M, et al. 1999. Interaction of diclofenac and quinidine in monkeys: Stimulation of diclofenac metabolism. Journal of Pharmacology and Experimental Therapeutics 291:1068-1074.
38. Venkatakrishnan K, Von Moltke LL, Obach RS, Greenblatt DJ. 2003. Drug metabolism and drug interactions: Application and clinical value of in vitro models. Current Drug Metabolism 4:423-459.
39. Witherow LE, Houston JB. 1999. Sigmoidal kinetics of CYP3A substrates: An approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat. Journal of Pharmacology and Experimental Therapeutics 290:58-65.